Yan Zong

Yan Zong

Auto-generated profile, based on publicly available information

Yan Zong

Department of Biomedical Engineering College of Future Technology Peking University Beijing China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Advanced Materials
Verified
Journal Article
Closed access
YZYan Zong
Yan Zong
YLYi Lin
Yi Lin
Tuo WeiTuo Wei
Tuo Wei
QCQIANG CHENG
QIANG CHENG

1 September 2025 in Nature Materials
Verified
Journal Article
Closed access
PDF file
YLYi Lin
Yi Lin
MLMengyao Li
Mengyao Li
ZLZijin Luo
Zijin Luo
YMYanan Meng
Yanan Meng
YZYan Zong
Yan Zong
QCQIANG CHENG
QIANG CHENG

16 June 2026 in Polymer Science & Technology
Verified
Journal Article
Open access
HZHaiping Zhong
Haiping Zhong
YZYan Zong
Yan Zong
HDHaoyu Du
Haoyu Du
JWJingzhi Wang
Jingzhi Wang
SQShuang Qu
Shuang Qu
SGShutao Guo
Shutao Guo
Acid-responsive drug delivery systems have evolved into versatile platforms for achieving spatially and temporally controlled drug activation by exploiting pathological and intracellular acidity. Despite significant advances in prodrug- and carrier-based systems, key challenges remain, including pH heterogeneity, limited understanding of structure–property–function relationships, and translational barriers. Future efforts will focus on developing ultra-sensitive and programmable systems with precisely tunable response thresholds. The integration of multi-stimuli responsiveness, logic-gated release mechanisms, and immunomodulatory functions is expected to enhance targeting specificity and therapeutic efficacy. In addition, improving biological barrier penetration and intracellular delivery remains critical, particularly for macromolecular therapeutics. Simplified, scalable designs with well-defined structures will be essential for clinical translation. Overall, acid-responsive drug delivery systems are transitioning toward intelligent, microenvironment-adaptive systems, offering significant potential for next-generation precision medicine.

8 January 2026 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
YZYan Zong
Yan Zong
YWYuqing Wang
Yuqing Wang
YLYi Lin
Yi Lin
QLQian Li
Qian Li
MLMengyao Li
Mengyao Li
QCQIANG CHENG
QIANG CHENG

2 August 2023 in Chinese Science Bulletin
Verified
Journal Article
Closed access
YZYan Zong
Yan Zong
Tuo WeiTuo Wei
Tuo Wei
QCQiang Cheng
Qiang Cheng
新型冠状病毒疫苗的研发成功将信使RNA(messenger RNA,mRNA)技术在全球范围推到了全新高度,更是直接推动了我国mRNA医药产业的快速崛起和发展。mRNA技术成功的背后离不开安全、高效的递送载体,尤其是脂质纳米颗粒(Lipid Nanoparticle,LNP),已获批(包括正式获批和紧急使用授权)的mRNA新冠疫苗大多受益于此递送体系,临床在研的mRNA药物项目超90%也同样依赖于LNP。作为mRNA递送领域炙手可热的明星载体,LNP自身的研发因此备受关注。当前mRNA-LNP技术在肝脏递送、肌肉注射的相关生物医学应用中较为成熟,但针对肝外组织的靶向递送相对处在研究早期。为了最大化扩宽mRNA药物的应用场景,研究者已经采取多种技术手段研发LNP靶向递送技术。基于此,本文重点讨论了当前组织靶向mRNA-LNP技术的研究策略,包括LNP处方优化、筛选新型脂质分子、靶向抗体修饰、给药方式优化等,并最后简要展望本领域未来的可能发展方向。